We are seeing an increase in dangerous microbes becoming resistant to antimicrobial drugs. To counter this threat, we must reduce our use of the drugs and explore innovative treatments that could one day replace them.
Healthy Debate Editor-in-Chief Seema Marwaha answers your questions on the effectiveness, safety and limitations of new antiviral pills to treat COVID-19.
Health Canada has a controversial plan for regulating new, complex health tech. Instead of the old vetting and approval process, a company and the agency would decide the standards as they go. Does this enable innovation or put patient safety at risk?
For many Canadians, important pharmaceuticals are too expensive. But initiatives by the Trudeau government and a federal regulator to combat this problem won't help Canadians access new, life-saving, but costly medicines. Just the opposite.
Canada spent a lot of money on a COVID-19 therapeutic that has been a flop. The deal reflects the financialized state of drug development and the nation-state's failure to stop it.
Canadian patients, scientists and health systems are paying the price for this failed policy experiment, which is not what our country needs at this critical moment.
If the government is serious about ensuring access to prescription drugs and vaccines to all, it must stand up to pressure from Big Pharma on pricing reforms.
Hydroxychloroquine was touted as a miracle cure for COVID-19 by Trump, then finished 2020 plagued with concerns about adverse cardiac events. But HCQ is a remarkable medication with a fascinating history.
The issue of drug shortages is a critical one and deserves a sober, evidence-based policy discussion by governments and experts. Generic drug manufacturing should not be nationalized for three reasons.
This pandemic, like the Spanish flu at the height of the Progressive era, is a chance for a burst of creativity in policy-making and a commitment to building new institutions.